The DCGI has granted permission to the Serum Institute of India to manufacture the Sputnik Covid-19 vaccine in India for examination, test and analysis with certain conditions, PTI reported.
The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, in Russia for developing Sputnik V at its licensed Hadapsar facility. The company had submitted an application to the DCGI in this regard on Thursday.
According to the four conditions set by the DCGI, the Serum Institute will have to submit a copy of the agreement between it and the Gamaleya Research Institute of Epidemiology and Microbiology for transfer of cell bank and virus stock and submit the copy of agreement for technology transfer with Gamaleya.